FDA Expands HPV Primary Screening Options - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Expands HPV Primary Screening Options

Regulatory action broadens available approaches for cervical cancer screening in US clinical practice.

  • By

  • Kathryn Wighton

  • February 4, 2026

  • 2 min

Share

  • 1

    The FDA approved the Aptima HPV assay for primary HPV screening, expanding options beyond Pap testing and co-testing.

  • 2

    The Aptima HPV assay detects messenger RNA, making it the only FDA-approved HPV test targeting RNA instead of DNA.

  • 3

    An estimated 13,490 new invasive cervical cancer cases are expected in the US in 2026, with 4,200 deaths potentially preventable through screening.

  • 4

    A large study involving over 650,000 women showed the Aptima HPV assay's sensitivity is comparable to DNA-based HPV tests.

  • 5

    Hologic's testing options allow providers to choose screening methods based on patient age, access, and risk factors.

Original Source(s)

FDA Expands HPV Primary Screening Options

  • by Kathryn Wighton

  • February 4, 2026

Related Content

Emergency diagnosis may flag poor outcomes beyond cancer

Across 13 noncancer conditions, emergency diagnosis was common and associated with higher 1-year mortality.

Menopause may be underdocumented in EHRs

Surveys captured nearly 7 times as many menopause observations as structured clinical records, with high agreement when both sources identified menopause.

Ovulation may shift preferences toward conspicuous luxury

Across 3 studies, higher fertility was associated with greater preference for luxury when it was visible, personally relevant, and potentially noticeable to others.